Partnering with the SON for Lutetium-177 Production

The SIF funding will cover part of the cost of the design, installation, and operation of Bruce Power’s Isotope Production System in Unit 7, which was installed and began commercial production of lutetium-177 in late 2022. The IPS was developed by Isogen, a joint venture between Framatome and Kinectrics, allowing isotopes to be produced on a large scale within existing Bruce Power nuclear infrastructure.

Importantly, Bruce Power partnered with the Saugeen Ojibway Nation (SON) to market the medical isotopes produced with the IPS through an arrangement named “Gamzook’aamin aakoziwin” or “We are teaming up on the sickness.” The Bruce Power – SON partnership includes an equity stake for SON and a revenue-sharing program that directly benefits the community. The SIF funding for the CMIE enables the SON’s acquisition of that equity.

Saugeen Ojibway Nation (SON)